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Abstract: Trachoma is a blinding eye disease caused by the bacterium 
Chlamydia trachomatis. The current global elimination of trachoma 
initiative includes the use of mass drug distribution of azithromycin in 
areas where the prevalence of follicular trachoma is >10% in children 
aged 1-9 years. This study aims to investigate the high quality evidence of 
whether mass drug administration for trachoma causes the development 
of azithromycin resistance in S pneumoniae.  Secondary objectives 
include (1) changes in the overall S pneumoniae prevalence and (2) 
concomitant development of non-macrolide resistance. Six databases 
were searched for articles relevant to the study question. Studies were 
screened and findings recorded using the PRISMA flow diagram and the 
Cochrane data collection checklist. Studies were only included if they 
included both a control and experimental group. Two risk of bias tools 
were used for quality appraisal of each study. After reviewing all studies, 
four were included in the final analysis, including one randomized control 
trial, two cluster-randomized trials and one prospective cohort. Findings 
showed decreased S pneumoniae prevalence and increased azithromycin 
resistant isolates following mass drug administration. This review shows 
that mass drug administration for trachoma can lead to a transient rise in S 
pneumoniae azithromycin resistance with a possible reduction in overall S 
pneumoniae prevalence. There is also evidence of macrolide-induced 
tetracycline and clindamycin resistance. The clinical impact of these 
findings remains unclear and further studies need to be performed to 
establish the significance. 
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Introduction 
Trachoma, a blinding eye disease caused by the 
bacterium Chlamydia trachomatis, causes blindness or 
visual impairment in an estimated 1.9 million people and 
is commonly seen in developing areas (WHO, 2018; 
Trachoma, 2006). Infection by C trachomatis serotypes 
A, B, or C results in prolonged conjunctival 
inflammation causing mucopurulent keratoconjunctivitis 
(Mohammadpour et al., 2016). The infection causes 
destruction of normal conjunctival epithelium resulting 
in replacement of subepithelial stroma with type IV and 
V collagen (Whittum-Hudson et al., 1986). Recurrent 
infections over several years can lead to extensive eyelid 
scarring and subsequently trichiasis, or inversion of 
eyelashes, which can rub against the eyeball and cause 
corneal scarring. This can progress to irreversible 
opacities, visual impairment and blindness (WHO, 
2018). This progression of the disease can be graded 
based on the World Health Organization’s (WHO) 




grading of clinical manifestations: Follicular Trachoma 
(TF), trachomatous intense, trachomatous scarring, 
trichiasis and corneal opacity. 
Pre-school aged children are commonly affected by 
trachoma in endemic areas and visual impairment from 
recurrent infections over time is seen at the ages of 30 to 
40 years (WHO, 2018). In 1993, the WHO initiated the 
SAFE strategy which promotes Surgery for trichiasis, 
Antibiotics for C. trachomatis infections, Facial 
cleanliness and Environmental improvements. In 1996, 
the WHO Alliance for the Global Elimination of 
Trachoma by 2020 (GET2020) was launched in an effort 
to implement SAFE and “the strengthening of national 
capacity through epidemiological surveys, monitoring, 
surveillance, project evaluation and resource 
mobilization” (WHO, 2018).  
Through the SAFE strategy, the antibiotic of choice 
is azithromycin for the treatment of trachoma, though 
topical tetracycline can also be used when needed in 
populations where azithromycin is contraindicated. As 
part of the GET2020 elimination efforts, Mass Drug 
Administration (MDA) with azithromycin is advised. 
Children aged 1-9 years old are screened for follicular 
trachoma and areas found to have a TF prevalence > 
10% undergo annual MDA for three years. Treatment is 
given to the entire district with a recommended coverage 
level of 80% of the eligible population. If TF prevalence 
is < 10%, then treatment is only implemented at the 
community level (WHO, 2006a; 2004). The threshold 
for discontinuing treatment is a TF prevalence < 5% in 
children aged 1-9 years.  
Over the past several years, there have been concerns 
regarding the development of bacterial resistance to 
azithromycin in the setting of trachoma MDA. One 
particularly concerning pathogen is Streptococcus 
pneumoniae, which is one of the causative organisms in 
cases of pneumonia, meningitis, otitis media and other 
infections. According to the WHO, in 2017, 15% of 
mortality of children under the age of five years was due to 
pneumonia, with S pneumoniae being the most common 
bacterial cause (WHO, 2016b). The highest burden of this 
mortality is borne by low-middle income countries. 
Several studies have documented S pneumoniae 
resistance to azithromycin in the setting of trachoma 
MDA. A systematic review by (Ho et al., 2015) 
focused on studies of nasopharyngeal S pneumoniae 
and included some cohort studies which did not have a 
comparison control group. A review by (O'Brien et al., 
2019) also included studies that did not have a 
comparison group. This study aims to investigate the 
high quality evidence of whether mass drug 
administration for trachoma causes the development of 
azithromycin resistance in S pneumoniae. Secondary 
objectives of this study are to (1) determine the 
prevalence of S pneumoniae carriage following 
exposure to azithromycin and (2) determine whether there 
is development of non-macrolide antibiotic resistance 
along with macrolide resistance in S pneumoniae in the 
setting of trachoma azithromycin MDA. 
Materials and Methods 
Eligibility Criteria  
Studies were selected for the review based on pre-
specified eligibility criteria. They were included if they 
were quantitative, investigated azithromycin resistance 
in S pneumoniae only in the setting of trachoma MDA 
and were published following the initiation of the SAFE 
strategy in 1993. The population of interest were those 
living in a trachoma endemic area with no specific age 
cut-off. Studies also needed to have a comparison 
control group. Studies were excluded if they were cross-
sectional, case reports, case-control, ecological, 
systematic reviews, ongoing or incomplete trials, opinion 
pieces, or letters. The language that the article was 
written in was not an exclusion criteria. 
Search and Information Sources 
Searches were performed independently by the author, 
Khan, using the electronic databases MEDLINE (Ovid), 
EMBASE (Ovid), Global Health, Africa-Wide 
Information, CINAHL Plus and Cochrane Library. The 
citation lists of key articles were also manually reviewed 
and relevant studies were searched. Search terms used for 
the databases included variations of: (azithromycin OR 
macrolide) AND resist* AND trachoma AND mass drug 
administration AND strep* pneumo*. No restrictions were 
placed in regards to language. Search timeframe was for 
all published studies until July 2018. Search terms were 
reviewed by second-reviewers Onen and Hilder. 
Study Selection and Data Collection 
Results obtained from the database search were 
screened for the inclusion criteria based on the title and 
abstract. Included studies were exported to the 
Mendeley platform and full text was subsequently 
reviewed for further inclusion and exclusion criteria. 
The Cochrane Effective Practice and Organisation of 
Care data collection template form (EPOC, 2002) was 
used to extract data from the included studies. All 
studies were reviewed for the inclusion/exclusion 
criteria by Khan, Onen and Hilder. 
Risk of Bias Assessment 
The validity of the eligible studies was completed 
independently by Khan to assess the reliability and 
adequacy of randomization, subject allocation, 
blinding, data collection and outcome assessment and 
reporting. Two quality appraisals were completed for 




each study, including the Critical Appraisal Skills 
Program (CASP) checklist (CASP, 2013) (for either 
randomized clinical trials or cohorts, as appropriate), 
the Cochrane Risk of Bias Tool for the randomized 
studies (Higgins et al., 2011) and the Risk of Bias in 
Non-Randomized Studies of Interventions (ROBINS-I) 
(Sterne et al., 2016) for cohort or non-randomized 
trials. An independent quality appraisal was also 
conducted by second-reviewer Onen. 
Synthesis of Data 
Heterogeneity of studies was assessed using the 
Higgins and Thompson’s I2 statistic through Review 
Manger 5.3. Clinical heterogeneity among studies was 
also evaluated. Results of the prevalence of S pneumoniae 
and the number of resistant isolates from each study were 
converted to percentages to allow for comparability of 
trends, which were subsequently plotted on a line graph.  
Results 
Study Selection 
In July 2018, database searches using MEDLINE 
(Ovid), EMBASE (Ovid), Global Health, Africa-Wide 
Information, CINAHL Plus and Cochrane Library, 
along with review of key paper references, identified a 
total of 160 articles after duplicates were removed. 
After reviewing the article titles and abstracts, 143 
records were excluded, leaving 17 to be reviewed by full 
text. Of the 17 articles that were reviewed, 13 were 
excluded based on the pre-defined exclusion criteria. 
Supplemental Table 1 outlines a detailed review of the 
excluded articles and reason for exclusion. The main 
reasons for exclusion were for not meeting the criteria 
of study design. The excluded studies were either cross 
sectional, letter, systematic review, ongoing trial, case 
series, case report and studies with no control group. 
Four full-text articles were included and were reviewed 
for study quality using the Cochrane Risk of Bias Tools 
and Critical Appraisal Skills Program checklist. Figure 
1 illustrates the PRISMA flow diagram of the citation 
review process.  
Characteristics of Included Studies 
Table 1 summarizes the characteristics of the 
included articles. Of the four studies that were included, 
two were cluster-randomized control trials, one was a 
randomized control trial and one was a prospective cohort. 
There were significant variations across all four studies in 
the frequencies of azithromycin administration, duration 
and follow-up. Two studies had given subjects a single 
dose of azithromycin after which follow-up data was 
collected (Chern et al., 1999; Coles et al., 2013). 
However, the other two studies administered biannual 
azithromycin for three years or quarterly azithromycin 
for one year (Haug et al., 2010; Skalet et al., 2010). 
Frequency of follow up ranged from 14 days to two years 
from the last dose of azithromycin (Chern et al., 1999; 
Haug et al., 2010). The sample size varied significantly 
among the studies, ranging from 31 to 486. Only three 
studies were able to achieve the recommended 
azithromycin coverage target of greater than 80%    
(Chern et al., 1999; Coles et al., 2013; Haug et al., 2010).  
Risk of Bias  
Two critical appraisal tools were used to assess each 
study. All studies addressed a clear question, had 
appropriate patient assignment and follow up. Blinding 
participants was not possible in all three randomized 
studies due to the nature of the study design (Chern et al., 
1999; Coles et al., 2013; Haug et al., 2010; Skalet et al., 
2010). The Cochrane tools, Risk of Bias Tool for 
randomized trials and the Risk of Bias in Non-
Randomized Studies – of Intervention, were used for the 
respective studies. Overall, all studies had a moderate 
risk of bias. Tables 2 and 3 summarize the appraisal.  
 
Table 1: Characteristics of the included studies 
        Initial sample size 
   Treatment Treatment  Test for Sample ------------------------ Treatment 
Source Country Study design population frequency Follow-up resistance population Treatment Control Coverage 
Chern et al. Nepal Randomized Children aged Single Baseline E-test Children aged 91 31 100% 
(1999)  control trial 1-10 years  14 days  1-10 years  
Coles et al. Tanzania Prospective Residents Single Baseline Kirby-Bauer Children 486 468 90% 
(2013)  cohort aged > 1 year  1 month disk < 5 years 
     3 months diffusion 
     6 months E-test   
Haug et al. Ethiopia Cluster-randomized Residents Biannual for 24 monthsa Sensititre Children 1-5 120 120 Baseline: 89.6% 
(2010)  trial with repeated aged > 1 year 3 years 36 months  years   6 months: 93.2% 
  cross sections   42 months     12 months: 96% 
     54 months     18 months: 88.5% 
          No data for 24 
          and 36 months 
Skalet et al. Ethiopia Cluster-randomized Children aged Quarterly for  Baselineb E-test Children  110 120 Baseline: 72.8% 
(2010)  control trial with 1-10 years 1 year 12 months  10 years   3 months: 76.3% 
  repeated cross sections        6 months: 80.4% 
          9 months: 78.2% 
a Specimen collected in control group only at 24 and 36 months; b No baseline specimens from control group 




Table 2: Cochrane Risk of Bias assessment for randomized studies (Higgins et al., 2011) Summary of the quality appraisal of the three randomized studies 
   Blinding of Blinding of  
 Random sequence Allocation participants and outcome Incomplete Selective 
 Generation concealment personnel assessment outcome data reporting 
 (selection bias) (selection bias) (performance bias) (detection bias)  (attrition bias) (reporting bias) Other bias 
Chern et al. (1999)        
Haug et al. (2010)       a 
Skalet et al. (2010)       b 
a High risk of contamination; b High risk of cross over bias; Low risk;  Unclear risk;  High risk 
 
Table 3: Risk of bias in non-randomized studies – intervention (Sterne et al., 2016) 
 Risk of bias pre-intervention and at-intervention  Risk of bias post-intervention  
 ------------------------------------------------------------------------------ ---------------------------------------------------------------------- 
  Bias in  Bias due to   Bias in 
  selection of Bias in deviations  Bias in selection of 
 Bias due to participants classification from intended Bias due to measurement the reported Overall 
Study confounding into the study of interventions interventions missing data of outcomes result Assessment 
Coles et al. (2013) Serious Low Low Low Serious Moderate Low Moderate 




Fig. 1: PRISMA flow diagram (Moher et al., 2009); a Review of references in key papers 
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Fig. 3: Prevalence of azithromycin resistant S pneumonia; * p  0.001 
 
Outcomes of Included Studies 
S pneumoniae Prevalence 
Figure 2 illustrates the prevalence of S pneumoniae 
across the four studies. In the prospective cohort by 
Coles et al. there was a statistically significant fall in 
prevalence in both control and treatment groups at three 
months where the treatment group had a higher 
prevalence (p < 0.001). Haug et al. showed the 
prevalence of S pneumoniae was lower in the treated 
group vs comparison; however, there was no significant 
difference between 24 and 36 months or 36 and 54 
months as reported by the authors, which suggested a 
“constant rate of pneumococcal carriage”.  




















































































































































































































S pneumoniae Azithromycin Resistance 
Figure 3 summarizes the azithromycin resistance 
pattern observed in the four studies. In the study by   
Chern et al. on follow-up after treatment, 42.9% of 
isolates of the treated group were resistant to azithromycin 
compared to 0% in the control group. P values and 
confidence intervals were not provided for these findings. 
Coles et al. reported increasing azithromycin resistance in 
the MDA group as compared to the non-MDA group, 
which was significant. After multivariate analyses done by 
the authors to adjust for the head of household’s education 
status and distance to fresh water source, the MDA-
exposed group had a two-fold greater odds of resistance 
at one and three months and five-fold at six months. 
These findings were significant by the reported 
confidence intervals. Both Haug et al. and Skalet et al. 
also demonstrated a statistically significant higher 
prevalence of azithromycin resistance in the treatment 
group following azithromycin administration.  
Resistance of S pneumoniae to Other Antimicrobials 
The four included studies also assessed for the 
development of resistance to other antimicrobials in the 
setting of MDA. One study reported no development of 
penicillin resistance in either group at baseline or at 
follow up (Chern et al., 1999). Another study reported 
rare penicillin resistance ranging from 0-1.9% without 
noting any consistent pattern (Coles et al., 2013). 
Neither of the remaining studies noted any measurable 
change in penicillin resistance over the course of the 
study (Haug et al., 2010; Skalet et al., 2010).  
One study tested for co-trimoxazole resistance and 
reported statistically significant, greater resistance in the 
non-MDA group at one month and six months of follow 
up (Coles et al., 2013). There was also a reported rise in 
the number resistant to both azithromycin and co-
trimoxazole over the six months in both groups, although 
reportedly more rapid development in the azithromycin-
treated group. Another study did not note any significant 
change in the resistance pattern to trimethoprim-
sulfamethoxazole (Haug et al., 2010).  
Tetracycline resistance was measured by two of the 
included studies. One study reported that the treatment 
group had greater resistance levels six months after the 
final three-year biannual azithromycin treatment than 
compared to the untreated group (p < 0.001) (Haug et al., 
2010). In this study, a rise in resistance was noted from 
24 to 36 months, but this subsequently declined from 36 
to 54 months. However, this finding was not significant. 
Another study also reported a significant increase in 
resistance to tetracycline from 15.2 to 35.5% in the treated 
group (p = 0.04), although this level was not significantly 
greater than the control group (Skalet et al., 2010). 
Clindamycin resistance was tested in one study and 
was significantly increased in the treatment group after 
mass azithromycin distribution (Skalet et al., 2010). 
Resistance level increased from 1.5 to 16.9% at 12 
months (p = 0.02). However, when compared to the 
control group, this did not reach statistical significance 
(Skalet et al., 2010). Another study found that 34.5% of 
azithromycin resistant isolates were also resistant to 
clindamycin at six months after the final three-year 
biannual treatment (Haug et al., 2010). This number 
increased to 60.0% at 54 months, although this change 
was not reported to be significant. 
Synthesis of Results 
For the purposes of this review, a meta-analysis and 
random-effects models were not completed due to the 
significant baseline variability in the eligible studies. All 
studies had different time points of follow-up. There were 
also different frequencies of azithromycin administration 
across studies. Furthermore, there were not enough studies 
to perform a combined analysis. The I2 value that was 
attempted was > 50%, suggesting substantial heterogeneity. 
Discussion 
This review shows that even when only high quality 
studies are included, there is still evidence of S pneumoniae 
resistance to azithromycin in the setting of mass drug 
administration for trachoma. This pattern is seen in all the 
included studies despite the variations in the azithromycin 
dosing frequency and time between treatment and follow-
up. Furthermore, this data may suggest the possibility that a 
greater number of azithromycin doses can lead to a greater 
prevalence of resistant S pneumoniae. The study with six 
azithromycin doses had a higher prevalence of resistant 
isolates than in the studies with only a single dose. 
However, it should be noted that comparability across the 
four studies is limited. In a longitudinal prospective cohort 
by (Hare et al., 2013) a “cumulative dose response effect” 
was seen on S pneumoniae resistance. 
The possibility of a short-lived rise in resistant S 
pneumoniae may also be considered from this study’s 
findings. The longest period of follow-up was two years 
from the last dose of azithromycin, during which there 
was a decline in prevalence after one year. There was 
also a noted decline in the rate of resistance development 
at six months after a single dose. However, some of these 
findings lack significance and further longitudinal studies 
would need to be conducted to evaluate this trend.  
Aside from the treatment of trachoma, there may be 
some beneficial secondary effects from azithromycin MDA. 
In this study, the data on carriage rates of S pneumoniae 
isolates, both susceptible and resistant, is variable. There is 
some suggestion for a decline in prevalence or a constant 
rate of carriage, though most of this data did not reach 
statistical significance. Pneumococcal colonization has been 
suggested to be a risk factor for developing pneumococcal 
disease (Bogaert et al., 2004; Petraitiene et al., 2015). In a 
2015 study in Lithuania, preschool children with S 




pneumoniae nasopharyngeal colonization were associated 
with longer duration of respiratory tract illness recovery and 
higher frequencies of pneumonia, sinusitis and acute otitis 
media (Petraitiene et al., 2015). Given that azithromycin 
could possibly cause a reduction in S pneumoniae 
prevalence, there may be some benefit from mass drug 
administration. Consideration must be made that reduction 
of one bacteria can give way to the expansion and 
replacement of that niche with other bacterial colonizers 
such as Staphylococcus aureus, Haemophilus influenzae 
and Neisseria meningitides (Bogaert et al., 2004; 
Veenhoven et al., 2003). 
There is limited data on whether colonized resistant S 
pneumoniae isolates lead to the development of 
antimicrobial resistant clinical disease. However, as noted 
above, S pneumoniae colonization is a risk factor for 
pneumococcal infection. In a study in Ohio of children in 
day care centers, carriers of multiply resistant S pneumoniae 
were more likely to have frequent otitis media infections 
and otitis media episodes that were not responsive to 
antimicrobials (Reichler et al., 1992). However, these 
isolates were macrolide sensitive, but included resistances 
to beta-lactams. In a retrospective observational study by 
(Cilloniz et al., 2015) subjects with macrolide resistant 
community-acquired pneumonia were not more severely ill 
nor had worse outcomes. In his review of macrolide-
resistant S pneumoniae, (Niederman, 2015) also concludes 
that “even if macrolide-resistant pneumococci are common 
in [community acquired pneumonia], they do not affect the 
severity of illness on presentation”. 
Several studies have noted an association between 
increased macrolide consumption and increased 
macrolide and penicillin resistance (Barkai et al., 2005; 
Bronzwaer et al., 2002; García-Rey et al., 2002). In this 
review, there was no significant associated resistance to 
penicillin or co-trimoxazole. There was however 
concurrent increased resistance noted to tetracycline and 
clindamycin. These findings can be due to the known 
macrolide resistance mechanisms of pneumococcus. The 
tetM gene, which encodes a protective protein for the 
ribosome, leads to tetracycline resistance (Cillóniz et al., 
2016). This gene is on the same transposon which 
encodes erm(B) and/or mef(E), which confer macrolide 
resistance (Cillóniz et al., 2016). In regards to 
clindamycin, it has been noted previously that the 
erm(B) gene also allows for resistance to lincosamides 
due to its broad resistance activity (Schroeder and 
Stephens, 2016). Macrolide-induced multi-drug resistance 
may be concerning for the treatment of other illnesses. 
Further studies will need to be done to elucidate the 
clinical implications of these findings.  
There are several limitations of this review. Firstly, there 
is an insufficient number of included studies, of which only 
three are randomized studies. Furthermore, the cluster-
randomized design of two of the articles followed groups 
rather than individuals, making the applicability of data at 
the individual level difficult. Another limitation includes 
significant heterogeneity between the studies in duration, 
dosing frequency and frequency of follow-up. This limits 
the comparability of data across studies.  
Conclusion 
This review demonstrates that there is development of 
azithromycin resistance in S pneumoniae in areas that 
receive mass drug administration for trachoma, although 
this may only be short-lived. Several points should be 
considered in weighing the risks and benefits of macrolide 
treatment, especially in the light of new evidence that 
showed reduction in childhood mortality from 
azithromycin distribution (Keenan et al., 2018). Further 
studies need to be performed to elucidate the clinical 
significance of macrolide-resistant S pneumoniae carriage. 
Studies or monitoring systems should be in place to 
research the effects of such isolates and whether they 
result in significant clinical disease. 
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